DD298055A5 - Methode und nuetzlicher apparat zur darstellung pharmazeutischer zusammensetzungen - Google Patents
Methode und nuetzlicher apparat zur darstellung pharmazeutischer zusammensetzungen Download PDFInfo
- Publication number
- DD298055A5 DD298055A5 DD90344026A DD34402690A DD298055A5 DD 298055 A5 DD298055 A5 DD 298055A5 DD 90344026 A DD90344026 A DD 90344026A DD 34402690 A DD34402690 A DD 34402690A DD 298055 A5 DD298055 A5 DD 298055A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- chamber
- particles
- allergen
- solution
- antigen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 107
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- 235000016709 nutrition Nutrition 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract description 77
- 102000036639 antigens Human genes 0.000 claims abstract description 75
- 108091007433 antigens Proteins 0.000 claims abstract description 75
- 239000003937 drug carrier Substances 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims description 137
- 239000000243 solution Substances 0.000 claims description 114
- 239000013566 allergen Substances 0.000 claims description 80
- 239000012530 fluid Substances 0.000 claims description 76
- 230000005298 paramagnetic effect Effects 0.000 claims description 70
- 238000010828 elution Methods 0.000 claims description 69
- 239000007788 liquid Substances 0.000 claims description 67
- 238000000926 separation method Methods 0.000 claims description 46
- 229960000301 factor viii Drugs 0.000 claims description 43
- 102000001690 Factor VIII Human genes 0.000 claims description 31
- 108010054218 Factor VIII Proteins 0.000 claims description 31
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 28
- 238000005406 washing Methods 0.000 claims description 28
- 230000005291 magnetic effect Effects 0.000 claims description 25
- 229940124135 Factor VIII inhibitor Drugs 0.000 claims description 24
- 239000000872 buffer Substances 0.000 claims description 21
- 206010020751 Hypersensitivity Diseases 0.000 claims description 18
- 230000000890 antigenic effect Effects 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 239000004471 Glycine Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 230000003472 neutralizing effect Effects 0.000 claims description 14
- 238000006386 neutralization reaction Methods 0.000 claims description 13
- 238000011084 recovery Methods 0.000 claims description 8
- 208000030961 allergic reaction Diseases 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 230000005484 gravity Effects 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 150000003839 salts Chemical group 0.000 claims description 2
- CDZHZLQKNAKKEC-UHFFFAOYSA-N [bis(hydroxymethylamino)methylamino]methanol Chemical compound OCNC(NCO)NCO CDZHZLQKNAKKEC-UHFFFAOYSA-N 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 16
- 230000027455 binding Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 208000026935 allergic disease Diseases 0.000 description 9
- 239000012149 elution buffer Substances 0.000 description 9
- 230000007815 allergy Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000006148 magnetic separator Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 5
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 5
- 235000003484 annual ragweed Nutrition 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 235000006263 bur ragweed Nutrition 0.000 description 5
- 235000003488 common ragweed Nutrition 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 235000009736 ragweed Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 229960004784 allergens Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011173 large scale experimental method Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 229940121854 Factor VII inhibitor Drugs 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000003705 Senecio vulgaris Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QJVKUMXDEUEQLH-UHFFFAOYSA-N [B].[Fe].[Nd] Chemical compound [B].[Fe].[Nd] QJVKUMXDEUEQLH-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940005779 factor viii injection Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910001172 neodymium magnet Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C1/00—Magnetic separation
- B03C1/02—Magnetic separation acting directly on the substance being separated
- B03C1/28—Magnetic plugs and dipsticks
- B03C1/288—Magnetic plugs and dipsticks disposed at the outer circumference of a recipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C2201/00—Details of magnetic or electrostatic separation
- B03C2201/26—Details of magnetic or electrostatic separation for use in medical or biological applications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fuel Cell (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40748789A | 1989-09-14 | 1989-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD298055A5 true DD298055A5 (de) | 1992-02-06 |
Family
ID=23612303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD90344026A DD298055A5 (de) | 1989-09-14 | 1990-09-14 | Methode und nuetzlicher apparat zur darstellung pharmazeutischer zusammensetzungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5336760A (ja) |
| EP (1) | EP0491858A1 (ja) |
| JP (1) | JPH05500512A (ja) |
| CA (1) | CA2067158A1 (ja) |
| DD (1) | DD298055A5 (ja) |
| IE (1) | IE903354A1 (ja) |
| PL (1) | PL286914A1 (ja) |
| WO (1) | WO1991004059A2 (ja) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5536475A (en) * | 1988-10-11 | 1996-07-16 | Baxter International Inc. | Apparatus for magnetic cell separation |
| US5240856A (en) * | 1991-10-23 | 1993-08-31 | Cellpro Incorporated | Apparatus for cell separation |
| US5672481A (en) * | 1991-10-23 | 1997-09-30 | Cellpro, Incorporated | Apparatus and method for particle separation in a closed field |
| AU708810B2 (en) * | 1994-03-14 | 1999-08-12 | Nexell Therapeutics Inc. | Method and apparatus for semi-automated cell separation |
| JP3962789B2 (ja) * | 1995-02-21 | 2007-08-22 | ダブリュー． シディキー，イクバール | 磁性粒子を利用した混合／分離装置及びその方法 |
| US6884357B2 (en) | 1995-02-21 | 2005-04-26 | Iqbal Waheed Siddiqi | Apparatus and method for processing magnetic particles |
| US6500343B2 (en) | 1995-02-21 | 2002-12-31 | Iqbal W. Siddiqi | Method for mixing and separation employing magnetic particles |
| US5835329A (en) * | 1995-06-05 | 1998-11-10 | Solid Phase Sciences Corporation | Apparatus for agitation separation of magnetic particles |
| US6036857A (en) * | 1998-02-20 | 2000-03-14 | Florida State University Research Foundation, Inc. | Apparatus for continuous magnetic separation of components from a mixture |
| EP0941766B1 (en) * | 1998-03-12 | 2006-12-20 | Miltenyi Biotec GmbH | Micro column system for magnetic separation |
| US6346196B1 (en) | 1998-07-01 | 2002-02-12 | The Board Of Governors For Higher Education State Of Rhode Island Providence Plantations | Flow-through, hybrid magnetic field gradient, rotating wall device for enhanced colloidal magnetic affinity separations |
| US6193892B1 (en) | 1999-03-03 | 2001-02-27 | Promega Corporation | Magnetic separation assembly and method |
| US6635181B2 (en) | 2001-03-13 | 2003-10-21 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Continuous, hybrid field-gradient device for magnetic colloid based separations |
| ES2253533T3 (es) * | 2001-09-06 | 2006-06-01 | Adnagen Ag | Procedimiento para la deteccion cualitativa y/o cuantitativa de celulas. |
| DE10143775A1 (de) * | 2001-09-06 | 2003-04-10 | Adnagen Ag | Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Darmkrebs |
| DE10143776A1 (de) * | 2001-09-06 | 2003-04-03 | Adnagen Ag | Verfahren und Kit zur Diagnostik oder Behandlungskontrolle von Brustkrebs |
| AU2002219137A1 (en) * | 2001-11-22 | 2003-06-10 | Adnagen Ag | Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer |
| US7601491B2 (en) * | 2003-02-06 | 2009-10-13 | Becton, Dickinson And Company | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
| CA2575784A1 (en) * | 2004-08-03 | 2006-02-16 | Becton, Dickinson And Company | Use of magnetic material to fractionate samples |
| KR101423936B1 (ko) | 2009-03-11 | 2014-07-29 | (주)바이오니아 | 실시간 핵산 분석 통합 장치 및 이를 이용한 타겟 핵산의 검출방법 |
| KR101870311B1 (ko) | 2012-03-09 | 2018-06-25 | (주)바이오니아 | 핫스타트 역전사반응 또는 핫스타트 역전사 중합효소 연쇄반응용 조성물 |
| KR101545848B1 (ko) | 2012-04-09 | 2015-08-21 | (주)바이오니아 | 핵산중합효소로 핵산을 검출하는데 사용되는 고민감도 핵산준비방법 |
| CN107530486B (zh) * | 2015-05-08 | 2020-12-11 | 生物磁溶液有限公司 | 免疫磁性细胞分离的装置和方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905865A (en) * | 1972-07-27 | 1975-09-16 | Merck & Co Inc | Cell and vaccine production |
| SU626043A1 (ru) * | 1975-04-07 | 1978-09-30 | Государственный научно-исследовательский институт горнохимического сырья | Аппарат дл магнитной обработки жидкости |
| US3970518A (en) * | 1975-07-01 | 1976-07-20 | General Electric Company | Magnetic separation of biological particles |
| US4219411A (en) * | 1978-09-18 | 1980-08-26 | California Institute Of Technology | Cell sorting apparatus |
| GB2045431B (en) * | 1979-02-26 | 1983-04-20 | Technicon Instr | Immunoassay utilising two particulate reagents |
| DE3200988A1 (de) * | 1982-01-14 | 1983-07-28 | Thomas A. Dr. 6900 Heidelberg Reed | Verfahren und vorrichtung zur abtrennung von organischen stoffen aus einer suspension oder loesung |
| US4861705A (en) * | 1983-01-31 | 1989-08-29 | Yeda Research And Development Company, Ltd. | Method for removing components of biological fluids |
| US4628037A (en) * | 1983-05-12 | 1986-12-09 | Advanced Magnetics, Inc. | Binding assays employing magnetic particles |
| ATE66249T1 (de) * | 1984-01-12 | 1991-08-15 | Chiron Corp | Hybridom-zellinien und monoklonale antikoerper gegen faktor-viii-c. |
| DE122004000028I1 (de) * | 1984-01-12 | 2004-09-30 | Chiron Corp | F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen. |
| US4740371A (en) * | 1984-09-17 | 1988-04-26 | International Institute Of Cellular And Molecular Pathology | Treatment of allergy |
| US4710472A (en) * | 1985-09-25 | 1987-12-01 | The United States Of America As Represented By The Secretary Of The Navy | Magnetic separation device |
| US4904391A (en) * | 1985-10-09 | 1990-02-27 | Freeman Richard B | Method and apparatus for removal of cells from bone marrow |
| SU1366218A1 (ru) * | 1986-05-11 | 1988-01-15 | Государственный проектно-конструкторский институт "Гипромашуглеобогащение" | Магнитный сепаратор |
| IL83192A (en) * | 1986-07-18 | 1992-11-15 | Gist Brocades Nv | Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies |
| US4846786A (en) * | 1987-04-30 | 1989-07-11 | Massachusetts Institute Of Technology | Bioreactor containing suspended, immobilized species |
| EP0344270B1 (en) * | 1987-10-26 | 1994-11-30 | Baxter Diagnostics Inc. | Process for producing magnetically responsive polymer particles and application thereof |
| IL88309A0 (en) * | 1987-11-17 | 1989-06-30 | Scripps Clinic Res | Peptides for use in the purification of factor viii |
| US5108933A (en) * | 1988-09-16 | 1992-04-28 | Immunicon Corporation | Manipulation of colloids for facilitating magnetic separations |
-
1990
- 1990-09-14 DD DD90344026A patent/DD298055A5/de not_active IP Right Cessation
- 1990-09-14 CA CA002067158A patent/CA2067158A1/en not_active Abandoned
- 1990-09-14 PL PL28691490A patent/PL286914A1/xx unknown
- 1990-09-14 US US07/838,711 patent/US5336760A/en not_active Expired - Fee Related
- 1990-09-14 WO PCT/US1990/005228 patent/WO1991004059A2/en not_active Application Discontinuation
- 1990-09-14 JP JP2513768A patent/JPH05500512A/ja active Pending
- 1990-09-14 EP EP90914864A patent/EP0491858A1/en not_active Withdrawn
- 1990-09-14 IE IE335490A patent/IE903354A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991004059A2 (en) | 1991-04-04 |
| IE903354A1 (en) | 1991-04-10 |
| US5336760A (en) | 1994-08-09 |
| CA2067158A1 (en) | 1991-03-15 |
| PL286914A1 (en) | 1991-08-12 |
| WO1991004059A3 (en) | 1992-02-20 |
| EP0491858A1 (en) | 1992-07-01 |
| JPH05500512A (ja) | 1993-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD298055A5 (de) | Methode und nuetzlicher apparat zur darstellung pharmazeutischer zusammensetzungen | |
| DE3587477T2 (de) | Verfahren zur radioaktiven Markierung von diagnostischen und therapeutischen Agenzien die eine Chelatierungsgruppe enthalten. | |
| DE69534187T2 (de) | Sterile und pyrogenfreie säulen, gekoppelt mit einem protein, zum binden und entfernen von substanzen aus dem blut | |
| Van Leeuwen et al. | A new leucocyte group with two alleles: leucocyte group five | |
| DE69034042T2 (de) | System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung | |
| DE69531290T2 (de) | Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen | |
| WO1992005801A1 (en) | Primate erythrocyte bound monoclonal antibody heteropolymers | |
| DE3048815A1 (de) | Teilchen aus lipoidloeslichen stoffen, aus diesen teilchen und an diese gebundenen, biologisch aktiven stoffen bestehende gemische sowie verfahren zu deren herstellung | |
| US4512763A (en) | Method and apparatus for selective removal of constituents of blood | |
| DE2708985A1 (de) | Ermittlung von haeparin in blutplasma | |
| EP0403961B1 (de) | Magnetische Protein-Konjugate, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE3685818T2 (de) | Immunkomplextestverfahren. | |
| DE2824903A1 (de) | Immunanalyseverfahren | |
| DE60108316T2 (de) | Medizinische Kit und Methode zur Bestimmung eines Arzneimittels | |
| Hursting et al. | Tricyclic antidepressant-specific Fab fragments alter the distribution and elimination of desipramine in the rabbit: a model for overdose treatment | |
| Berndt | Probenecid binding by renal cortical slices and homogenates. | |
| DE3852683T2 (de) | Agglutinationstest. | |
| Gilden et al. | A technique for the elution of cell‐surface antibody from human brain tissue | |
| WO2006042507A1 (de) | Immunadsorber für die behandlung von entzündungen | |
| CN111471100A (zh) | 一种新型红细胞膜单抗生产方法及其加工装置 | |
| DE3919923A1 (de) | Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung | |
| Jones et al. | Reactions in vitro with target cells and subcellular fractions of enriched rat alloantibodies with enhancing activity | |
| EP0925110B1 (de) | Konjugat, geeignet zur bindung von substanzen | |
| Marcoullis et al. | Blocking and Binding Type Antibodies against All Major Vitamin B12‐Binders in a Pernicious Anaemia Serum | |
| DE10016877A1 (de) | (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PV | Patent disclaimer (addendum to changes before extension act) |